🧬 Section 511.10 · Thalassemia Syndromes: Management & Treatment

Nelson Textbook of Pediatrics 22nd Edition | Comprehensive management of thalassemia: transfusion guidelines (target pre-transfusion Hb 9.5-10.5 g/dL), iron chelation (deferasirox, deferoxamine, deferiprone), luspatercept, gene therapy (betibeglogene autotemcel/Zynteglo), hematopoietic stem cell transplant (HSCT), splenectomy indications, monitoring for iron overload (MRI T2*), endocrine complications.

🌐 paeds.online — Pakistan's Pediatric Platform

📋 30 Clinical Scenarios — Thalassemia Management & Treatment

📇 High‑Yield Review Cards (Thalassemia Management)

🩺 Clinical Scenarios in Thalassemia Management

Select a presentation for management guidance.

📋 Stepwise Management of Thalassemia Syndromes

🔑 Key Principles — Nelson Section 511.10
• Transfusion-dependent β-thalassemia (TDT): Start transfusions when Hb <7 g/dL with poor growth/bone changes. Goal pre-transfusion Hb 9.5-10.5 g/dL. Extended RBC phenotyping (C, E, K) to prevent alloimmunization.
• Iron chelation initiation: After 10-20 transfusions or ferritin >1000 ng/mL. Deferasirox (oral, 20-40 mg/kg/day) first-line. Deferiprone (oral TID) for cardiac iron.
• Monitoring: Serum ferritin q3 months, cardiac/liver MRI T2* annually (start at age 10 years).
• Luspatercept: TGF-β ligand trap; reduces transfusion burden in adults with TDT.
• Gene therapy (betibeglogene autotemcel): Lentiviral vector; approved for TDT patients ≥4 years without a matched sibling donor.
• HSCT: Curative with matched sibling donor; best outcomes in young children with low iron burden.

    ⚡ Reflex Prompts — Clinical Decisions in Thalassemia Management

    📖 Summary: Thalassemia Management & Treatment — Nelson Section 511.10